Skip to main content

Advertisement

Table 1 Patient characteristics, tumor characteristics and treatment modalities

From: The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy

   Group A (n = 67) Group B (n = 34)
Age (years) mean (min-max) 56 (36–82) 58 (42–79)
Sex M 60 31
  F 7 3
cT stage T1 2 1
  T2 17 13
  T3 27 7
  T4 21 13
cN stage N0 15 11
  N1 12 3
  N2 31 17
  N3 9 3
Tumor site glottic 3 2
  supraglottic 16 10
  hypopharynx 20 7
  oropharynx 24 14
  oral cavity 2 0
  nasopharynx 2 1
Radiotherapy 66 Gy/ 2 Gy 20 4
  70 Gy/1.4 Gy 4 1
  70 Gy/2 Gy 41 (2+ cisplatinum) 28 (1+cisplatinum)
  80.5 Gy/1.15 Gy 2 (1+cisplatinum) 1 (+ cisplatinum)
  1. Patient characteristics, tumor characteristics and treatment modalities are shown for Group A and Group B, both subgroups of the original study of CT-determined tumoral perfusion in patients with HNSCC treated by radiotherapy ± chemotherapy. Cisplatinum was given at a dose of 100 mg/m2 on days 1, 22 and 43.
  2. cT: clinical tumor stage. cN: clinical nodal stage. M: male. F: female. Gy: Gray.